



FOR IMMEDIATE RELEASE

Cancer Prevention Pharmaceuticals (CPP) to Conduct Business Development Meetings in San Francisco during JP Morgan Healthcare Conference

CPP seeking regulatory pathways in US and in EU

TUCSON, Arizona, December 5, 2019 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today its management team will be conducting partnering and business development meetings, January 13-16, 2020 in San Francisco concurrent with the annual JP Morgan Healthcare conference.

CPP's lead drug is CPP-1X/sul, for adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. FAP patients have no approved pharmaceutical therapies.

CPP recently completed a Phase 3 trial comparing the performance of the combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul) to each single agent alone in delaying progression to an FAP-related event, such as surgery. CPP is seeking regulatory pathways for approval in the US and EU. The safety profile of the combination did not significantly differ from that demonstrated by the single agents and did not pose any concerns for long-term use of the product.

About Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP's pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit www.canprevent.com.

Partnering and Business Development Inquiries: Christine Brannen, Cancer Prevention Pharmaceuticals, Inc., press@canprevent.com, +1.520.908.7774

###